- Price
- $16.10
- Day
- -1.35%
- Mkt Cap
- $4.55B
- 52W Range
- $14.19 – $42.50
- Volume
- 4.84M
- Beta
- 0.68
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Caris Life Sciences is rated a 'Buy' at ~$16.5, with a blended fair value estimate of $22.3, implying ~35% upside, and 23%-26% 2026 estimated revenue growth. CAI's proprietary WES/WTS/WGS technology and massive data advantage underpin its leadership in oncology diagnostics and pharma R&D services. Short-term signals are net positive: insider buying, a $100M share repurchase program, and a bullish put-call ratio against a downward technical trend.
Read full article
IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m.
Read full article